MediGene AG · LS:A40ESG
MediGene — 9M 2012 Earnings Presentation
15 slides from MediGene's earnings presentation, Nov 9, 2012
Slide 1: Analyst conference call: Results for the first 9 months of 2012
Analyst conference call Results for the first 9 months of 2012 November 9, 2012 Dr. Frank Mathias, CEO Peter Llewellyn-Davies, CFO
Slide 2: Forward-looking statements
This presentation contains forward-looking statements - that is, statements related to future, not past, events. These statements may be identified either orally or in writing by words as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "will", "may" or words of simila
Slide 3: Overview 9M 2012
Overview 9M 2012 Dr. Frank Mathias, CEO 3
Slide 4: Refocussing and restructuring completed. Progress in our three core projects.
Refocussing and restructuring completed. Progress in our three core projects. Refocussing of pipeline completed Monetization of Eligard® Successful concentration on three core projects: Veregen®: further market launches, approvals and partnerships EndoTAG®-1: co-development and marketing partnership
Slide 5: Major events since the start of Q3 2012
Major events since the start of Q3 2012 Veregen®: Market launch in Switzerland Marketing authorization in 8 additional European countries EndoTAG®-1: Co-development and commercialization agreement for Asia signed with SynCore Decision to up-scale the spray drying manufacturing process for commercial
Slide 6: Financial Report 9M 2012
Financial Report 9M 2012 Peter Llewellyn-Davies, CFO 6
Slide 7: Financial highlights for 9M 2012: Improved revenue and EBITDA
Financial highlights for 9M 2012: Improved revenue and EBITDA Continued operations: Total revenue increased by 60% to €4.8 million Veregen® revenue increased by 86% to €2.5 million EBITDA improved by 17% to €-6.3 million Discontinued operations: revenue of €5 million from Astellas Total operating ex
Slide 8: Increase in revenue from continued operations
Increase in revenue from continued operations In € million Veregen® In-market sales Total Veregen® revenue 36% 86% 9M 2011 9M 2012 9M 2011 9M 2012 Revenue (in T€) 9M 2011 9M 2012 Change Veregen® Product revenue (supply chain) 188 517 175% Royalties 1,001 1,358 36% Milestones 147 608 n.a. Veregen® re
Slide 9: Total operating expenses remain stable
Total operating expenses remain stable In € million R&D expenses SG&A expenses -1% 2% 5.2 5.2 5.6 5.7 9M 2011 9M 2012 9M 2011 9M 2012 Higher clinical, non-clinical Higher legal transaction and regulatory costs costs (Cowen) Higher consultancy fees Lower personnel and facility expenses 9
Slide 10: Improved EBITDA from continued operations
Improved EBITDA from continued operations In € million EBITDA (continued operations) EBITDA (total) -6.3 -7.6 14.5 -1.3 9M 2011 9M 2012 9M 2011 9M 2012 Includes €0.6 million pro rata revenue recognition of Eligard® Includes milestone payments from Astellas of €5 million in 9M 2012 (9M 2011: €20 mill
Slide 11: Financing secured beyond 2013
Financing secured beyond 2013 In € million 0.1 14.1 -4.4 22.2 -0.2 12.8 Cash as of Cash flow from Cash flow from Cash flow from Foreign exchange Cash as of Jan. 1, 2012 operating activities investing activities financing activities differences Sep. 30, 2012 Cash flow from operating activities incl
Slide 12: Confirmed financial guidance for 2012
Confirmed financial guidance for 2012 Guidance 2012 Revenue from continued operations greater than €5 million Revenue from discontinued operations €5 million loss in mid-single digit EBITDA (total) million range 12
Slide 13: Product and project outlook
Product and project outlook Veregen® Approvals and market launches in additional countries Additional marketing and partnership agreements Revenue growth EndoTAG®-1 Upscaling of the manufacturing process for commercially viable material in preparation for a global pivotal phase III trial in TNBC Rhu
Slide 14: Questions & Answers
medigene Questions & Answers
Slide 15: Medigene AG contact details
Medigene AG MediGene AG T +49 - 89 - 20 00 33 - 0 Lochhamer Straße 11 F +49 - 89 - 20 00 33 - 2920 82152 Planegg/Martinsried Planegg / Martinsried investor@medigene.com Germany www.medigene.com Listed on Frankfurt Stock Exchange (MDG, Prime Standard)